Literature DB >> 8263122

HIV-1 pseudotype virus containing a Cocal virus genome and an HIV envelope: construction, assay and use.

S Gregory1, R Collman, W James, S Gordon, F Gonzalez-Scarano, N Nathanson.   

Abstract

A method is described for the production and assay of pseudotype viruses between human immunodeficiency virus type 1 (HIV-1) and Cocal virus (COV), containing an HIV-1 envelope and a COV genome (COV(HIV)). COV(HIV) pseudotype virus is a useful tool for the investigation of a variety of questions regarding HIV entry into susceptible cells, including steps in virus binding, fusion, and internalization, and the role of molecules which inhibit entry. COV, a rhabdovirus closely related to vesicular stomatitis virus (VSV), replicated and caused cytopathic effect in primary cultures of human peripheral blood lymphocytes (PBLs) and monocyte-derived macrophages (MDM), and in human cell lines of lymphocytoid or monocytoid origin, making it an ideal candidate for pseudotype production. 174XCEM cells, which were permissive for selected macrophage-tropic strains as well as most lymphocyte-tropic strains of HIV-1, were used to produce stocks of putative pseudotype virus. To neutralize parental COV in these stocks, a rabbit antiserum was produced which had a neutralization index of > 10(7) at a dilution of 1:100. Using these methods, pseudotype viruses were produced with a titer of about 10(4) PFU per ml; these same stocks contained HIV-1 at a titer of about 10(5) TCD50 per ml and COV at a titer of about 10(8) PFU per ml. CD4-expressing HeLa cells were used to assay pseudotype stocks made with lymphocyte-tropic strains of HIV-1. The authenticity of the pseudotype stocks was validated by several controls, including their failure to register on congenic CD4-negative HeLa cells and their inhibition by monoclonal anti-CD4 antibodies such as Leu 3a.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8263122     DOI: 10.1016/0166-0934(93)90064-x

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  4 in total

1.  Biological characterization of human immunodeficiency virus type 1 clones derived from different organs of an AIDS patient by long-range PCR.

Authors:  M T Dittmar; G Simmons; Y Donaldson; P Simmonds; P R Clapham; T F Schulz; R A Weiss
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

2.  Adaptation of chimeric retroviruses in vitro and in vivo: isolation of avian retroviral vectors with extended host range.

Authors:  E V Barsov; W S Payne; S H Hughes
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding.

Authors:  P B Fischer; M Collin; G B Karlsson; W James; T D Butters; S J Davis; S Gordon; R A Dwek; F M Platt
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

4.  The role of myeloid receptors on murine plasmacytoid dendritic cells in induction of type I interferon.

Authors:  Rosalind E Seeds; Subhankar Mukhopadhyay; Ian M Jones; Siamon Gordon; Joanna L Miller
Journal:  Int Immunopharmacol       Date:  2011-01-31       Impact factor: 4.932

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.